In this special, live edition of the pharmaphorum podcast, recorded at the conclusion of Frontiers Health 2022, pharmaphorum Editor in Chief Jonah Comstock and pharmaphoru
Now that the COVID-19 pandemic has provided the industry with a solid foundation of experience with decentralised trials, it is appropriate to reflect and ask whether DCT studies are truly
In this episode of the pharmaphorum podcast series, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health.
Despite randomised clinical trials (RCTs) being the gold standard for drug approval studies, the shift towards precision medicine has increased the use of single-arm trials (SATs).